These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 15589886)

  • 1. Macroprolactinemia in women presenting with hyperandrogenic symptoms: Implications for the management of polycystic ovary syndrome.
    Escobar-Morreale HF
    Fertil Steril; 2004 Dec; 82(6):1697-9. PubMed ID: 15589886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Macroprolactinemia in the differential diagnosis of hyperprolactinemia].
    Toldy E; Löcsei Z; Szabolcs I; Kneffel P; Góth M; Szöke D; Kovács LG
    Orv Hetil; 2003 Oct; 144(43):2121-7. PubMed ID: 14661444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
    Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
    Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
    Robin G; Catteau-Jonard S; Young J; Dewailly D
    Gynecol Obstet Fertil; 2011 Mar; 39(3):141-5. PubMed ID: 21388855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non polycystic ovary syndrome-related endocrine disorders associated with hirsutism.
    Unluhizarci K; Kaltsas G; Kelestimur F
    Eur J Clin Invest; 2012 Jan; 42(1):86-94. PubMed ID: 21623779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polycystic ovary syndrome associated with remarkable hyperprolactinemia--case report].
    Owecki M; Sowiński J
    Pol Merkur Lekarski; 2004 Oct; 17(100):385-7. PubMed ID: 15690710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early diagnosis, presenting complaints, and management of hyperandrogenism in adolescents.
    Schroeder B
    Curr Womens Health Rep; 2001 Oct; 1(2):124-30. PubMed ID: 12112959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macroprolactinemia in childhood and adolescence: a cause of hyperprolactinemia.
    Tütüncüler F; Darendeliler F; Aygün M; Hekim N
    Turk J Pediatr; 2006; 48(2):143-7. PubMed ID: 16848115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome.
    Fraser IS; Kovacs G
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):813-23. PubMed ID: 15380149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome.
    Lowenstein EJ
    Dermatol Ther; 2006; 19(4):210-23. PubMed ID: 17004997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group.
    Farah L; Lazenby AJ; Boots LR; Azziz R
    J Reprod Med; 1999 Oct; 44(10):870-4. PubMed ID: 10554748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin secretion in polycystic ovary syndrome (PCOS).
    Szosland K; Pawlowicz P; Lewiński A
    Neuro Endocrinol Lett; 2015; 36(1):53-8. PubMed ID: 25789595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.
    Carmina E; Azziz R
    Fertil Steril; 2006 Jul; 86 Suppl 1():S7-8. PubMed ID: 16798288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia.
    Can M; Guven B; Atmaca H; Acıkgoz S; Mungan G
    Kaohsiung J Med Sci; 2011 May; 27(5):173-6. PubMed ID: 21527183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What every physician should know about polycystic ovary syndrome.
    Rosenfield RL
    Dermatol Ther; 2008; 21(5):354-61. PubMed ID: 18844713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women.
    Alvarez-Blasco F; Botella-Carretero JI; San Millán JL; Escobar-Morreale HF
    Arch Intern Med; 2006 Oct; 166(19):2081-6. PubMed ID: 17060537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgenization in patients with polycystic ovary syndrome].
    Gasparov AS; Pshenichnikova TIa; Alieva EA; Fedorova TA; Vetr M
    Acta Univ Palacki Olomuc Fac Med; 1990; 126():241-6. PubMed ID: 2151091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.